Silmitasertib - Senhwa Biosciences
Alternative Names: CX 4945Latest Information Update: 17 Jul 2024
At a glance
- Originator Cylene Pharmaceuticals
- Developer Cylene Pharmaceuticals; Penn State College of Medicine; Senhwa Biosciences; Stanford University School of Medicine
- Class 3-ring heterocyclic compounds; Antineoplastics; Antivirals; Carboxylic acids; Naphthyridines; Small molecules
- Mechanism of Action Casein kinase II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Community-acquired pneumonia; COVID 2019 infections
- Phase I/II Cholangiocarcinoma; Medulloblastoma
- Phase I Basal cell cancer
- Preclinical Acute myeloid leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
- No development reported Giant lymph node hyperplasia; Multiple myeloma; Solid tumours
Most Recent Events
- 11 Jul 2024 Senhwa Biosciences announces intention to apply for Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPD) for Silmitasertib for Neuroblastoma
- 11 Jul 2024 Senhwa Biosciences files an IND application with the US FDA for Solid tumour
- 11 Jul 2024 Senhwa Biosciences plans a phase I/II trial for Solid tumour (Combination therapy, In children, In adults, Second-line therapy or greater) in USA (PO)